Vitamin D and analogues in renal bone disease and implications for osteoporosis

Osteoporosis International

Volumn 7, Issue SUPPL. 3, 1997, Pages

  Kanis, J A ^a,b   McCloskey, E V ^a   Beneton, M N C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D;

CONFERENCE PAPER; HYPERPARATHYROIDISM; OSTEOPOROSIS; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; VITAMIN D DEFICIENCY;

AGED; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; MALE; OSTEOPOROSIS; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 0031452867     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03194368     Document Type: Article

References (55)

1. Kanis JA. Vitamin D analogues from renal bone disease to osteoporosis. Calcif Tissue Int 1997; in press.
2. Kanis JA. Pathogenesis of renal bone disease. MD thesis, University of Sheffield, UK, 1985.
3. 3 in renal bone disease. Clin Endocrinol 1977;7(Suppl):45-50.
4. Malluche HH, Ritz E, Lange HP, Kutshera J, Hodgson M, Seiffert U, et al. Bone histology in incipient and advanced renal failure. Kidney Int 1976;9:355-62.
5. Cundy T, Hand DJ, Oliver DO, Woods CG, Wright FW, Kanis JA. Who gets renal bone disease before beginning dialysis? BMJ 1985;290:271-5.
6. Ellis HA, Peart KM. Azotaemic renal osteodystrophy: a quantitative study on iliac bone. J Clin Pathol 1973;26:83-101.
7. Kanis JA, Cundy T, Hamdy NAT. Renal osteodystrophy. Baillieres Clin Endocrinol Metab 1988;2:193-241.
8. Malluche HH, Faugere M-C. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990;38:193-211.
9. Massry SG, Ritz E. The pathogenesis of secondary hyperparathyroidism of renal failure: is there a controversy? Arch Intern Med 1978;138:853-6.
10. Slatopolsky E, Calgar S, Pennell JP, Taggart DB, Canterbury JM, Reiss E, Bricker NS. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971;50:492-9.
11. Bricker NS. On the pathogenesis of the uremic state: an exposition of the 'trade-off hypothesis'. N Engl J Med 1972;286:1093-9.
12. Llach F. Massry SG, Singer FR, Kurokawa K, Kaye JH, Coburn JW. Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure: a possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab 1975;41:339-45.
13. Llach F, Massry SG. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 1985;61:601-6.
14. Portale AA, Booth BE, Halloran BP, Morris RC. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984;73:1580-9.
15. Lopez-Hilker S, Galceran T, Chan YL, Rapp N, Martin KJ, Slatopolsky E. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 1986;78:1097-102.
16. Cundy T, Hamdy NAT, Kanis JA. Factors modifying the secretion and action of parathyroid hormone in renal failure. Contrib Nephrol 1988;64:5-15.
17. 3. Kidney Int 1975;9:467-74.
18. Somerville PJ, Kaye M. Resistance to parathyroid hormone in renal failure: role of vitamin D metabolites. Kidney Int 1978;14:245-54.
19. 2 vitamin D inhibits parathyroid cell proliferation in experimental uraemia. Kidney Int 1989;35:1049-56.
20. 3 suppresses parathyroid hormone secretion from parathyroid cells in tissue culture. Endocrinology 1985;117:2114-9.
21. Silver J, Russell J, Sherwood LM. Regulation by vitamin D metabolites of messenger ribonucleic acid for pre-pro-parathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 1985;82:4270-3.
22. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation of vitamin D metabolites of parathyroid hormone gene transcription in vivo by the rat. J Clin Invest 1986;78:1296-301.
23. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984;74:2136-43.
24. 3 in normal man and in patients with renal failure. Ann Intern Med 1974;80:161-8.
25. Kanis JA, Cundy T, Earnshaw M, Henderson RG, Heynen G, Naik R, et al. Treatment of renal bone disease with 1-hydroxylated derivatives of vitamin D. Q J Med 1979;48:289-322.
26. 3 in renal osteodystrophy. In: Norman AW, Schaefer K, Coburn JW, DeLuca HF, Fraser D, Grigoleit H, von Herrath D, editors. Vitamin D: biochemical, chemical and clinical aspects relating to calcium metabolism. Berlin: deGruyter, 1977:657-666.
27. Sharman VL, Brownjohn AM, Goodwin FJ, Heately W, Manning RM, O'Riordan JLH, et al. Long-term experience of alfacalcidol in renal osteodystrophy. Q J Med 1982;51:271-8.
28. Kanis JA, Earnshaw M, Heynen G, Ledingham JGG, Russell RGG, Smith R, Walton RJ. Renal osteodystrophy in nondialysed adolescents: long-term treatment with 1-hydroxycholecalciferol. Arch Dis Child 1977;52:473-81.
29. 3 and its 1-alpha hydroxylated derivatives. BMJ 1977;I:78-81.
30. 3 in early renal failure. Annu Rev Med. 1992;43:227-37.
31. Naik RB, Cundy T, Robison BHB, Russell RGG, Kanis JA. Effects of vitamin D metabolites and analogues on renal function. Nephron 1981;28:17-25.
32. Hamdy NAT, Kanis JA, Beneton MNC, Brown CB, Juttman JR, Jordans JGM, et al. Effect of alfacalcidol on the natural history of renal bone disease in mild to moderate renal failure. BMJ 1995;310:358-63.
33. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HLF. Intestinal absorption and serum vitamin D metabolites in normal subjects and osteoporosis patients: effect of age and dietary calcium. J Clin Invest 1979;64:729-36.
34. Fox K, Tobin JD, Plato CC. Longitudinal study of bone loss in the second metacarpal. Calcif Tissue Int 1986;39:218-25.
35. Jones G, Nguyen T, Sambrook P, Kelly PJ, Eisman JA. Progressive loss of bone in the femoral neck of elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 1994;309:691-5.
36. Kanis JA, McCloskey EV. Evaluation of the risk of hip fracture.Bone 1996;18(Suppl 3):127-32.
37. Lips P, van Ginkel EC, Jongen MJM, Rubestrus A, van der Vijgh WJF, Netelenbos JC. Determinants of vitamin D status in patients with hip fracture and elderly control subjects. Am J Clin Nutr 1987;46:1005-10.
38. McKenna M. Differences in vitamin D status between countries in young adults and the elderly. Am J Med 1992;93:69-77.
39. Lips P, Obrant K. The pathogenesis and treatment of hip fractures. Osteoporos Int 1991;1:218-31.
40. Dawson-Hughes B, Dallai GE, Krall EA, Harris S, Sokoll LI, Falconer G. Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. Ann Intern Med 1991;115:505-12.
41. Lips P. Wiersinga A, van Ginkel FC, Jongen MIM, Netenlenbos JC, Hackeng WHL, et al. The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab 1988;671:644-50.
42. Lips P, Netelenbos JC, Jongen MJM, et al. Histomorphometric profile and vitamin D status in patients with fermoral neck fractures. Metab Bone Dis Rel Res 1982;4:89-93.
43. Hordon LD, Peacock M. Osteomalacia and osteoporosis in femoral head fracture. Bone Miner 1990;11:147-59.
44. Johnell O, Gullberg B, Kanis JA, et al. Risk factors for hip fracture in European women: the MEDOS study. J Bone Miner Res 1995;10:1802-15.
45. Tsai K, Heath HH, Kumar R, Riggs BL. Impaired vitamin D metabolism with aging in women: possible role in pathogenesis of senile osteoporosis. J Clin Invest 1984;73:1668-72.
46. Meunier P, Chapuy MC, Arlot ME, et al. Effects of a calcium and vitamin D supplement on non-vertebral fracture rate, femoral bone density and parathyroid function in elderly women [abstract]. J Bone Miner Res 1991;6:S135.
47. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:1081-1082.
48. Ooms ME. Osteoporosis in elderly women. MD thesis, Free University of Amsterdam.
49. Khaw K-T, Sneyd M-J, Compston J. Bone density, parathyroid hormone and 25-hydroxyvitamin D concentrations in middle aged women. BMJ 1992;305:273-7.
50. Ranstam J, Kanis JA. Influence of age and body mass on the effects of vitamin D on hip fracture risk. Osteoporos Int 1995;5:450-4.
51. 3 and calcium prevent hip fractures in elderly women. N Engl J Med 1992;327:1737-42.
52. Heikinheimo RJ, Inkovaara JA, Harju EJ, et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 1992;51:105-10.
53. Ooms MM, Roos JC, Bezemer PD, van der Vijgh WJF, Bouter LM, Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: a randomised double blind trial. J Clin Endocrinol Metab 1995;80:1052-8.
54. Kanis JA, Cooper C, Francis R, Hamdy N, Selby P, Torgerson D. The role of vitamin D and related compounds in the treatment of bone disease in the elderly. Bone 1993;15:727-8.
55. Torgerson D, Kanis JA. The cost effectiveness of preventing hip fractures using vitamin D and calcium. QJM 1995;88:135-9.